SCHEMBL26980565

SCHEMBL26980565

FC(F)(F)c1ccc(Cn2nc(-c3ccccc3)cc2-c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 3/20 0.51
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
STAT3 P40763 2/20 0.51
LMNA P02545 1/20 0.51
GCGR P47871 4/20 0.48
HDAC1 Q13547 3/20 0.47
POLB P06746 2/20 0.44
GALR3 O60755 1/20 0.44
GAA P10253 1/20 0.44
NPY1R P25929 1/20 0.44
NPY2R P49146 1/20 0.44
GLO1 Q04760 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26978302 0.86 HDAC3 (0.44) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL9071635 0.82 GCGR (0.75) GCGRCYP2C9
SCHEMBL2667875 0.82 GCGR (0.75) GCGRCYP2C9
SCHEMBL3631457 0.81 SMN1; SMN2 (0.56) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL4106614 0.81 SMN1; SMN2 (0.50) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL4684515 0.80 MEN1 (0.50) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL4682071 0.79 HDAC1 (0.50) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL2667879 0.78 GCGR (0.75) GCGRHDAC1
SCHEMBL17853353 0.77 POLB (0.71) SMN1; SMN2MEN1MAPTKMT2ASTAT3
SCHEMBL3631131 0.76 HDAC1 (0.48) SMN1; SMN2MEN1MAPTKMT2ASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2024-01-04 US claimed
WO-2022108980-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-27 WO claimed
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2024-01-04 US disclosed
WO-2022108980-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS PEBP1, ALOX15, ALOX15B SMN1; SMN2 3976/4885MEN1 4252/4885MAPT 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.